Grace Therapeutics, Inc.
GRCE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GRCE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRCE
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, with its lead candidate GTx-104 under regulatory review.
Key risk: Regulatory approval uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Grace Therapeutics, Inc..
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, with its lead candidate GTx-104 under regulatory review.
- Grace Therapeutics is focused on rare and orphan diseases, applying proprietary formulations to approved compounds to improve clinical outcomes [sec_mda · as of 2026-08-13].
- The company's pipeline includes three clinical-stage candidates (GTx-104, GTx-102, GTx-101) supported by over 79 granted and pending patents worldwide [sec_mda · as of 2026-06-18].
- As of 2026-06-30, the company reported cash and equivalents of $13.8M, net income of -$15.8M, and shareholders' equity of $63.9M [sec].
- GTx-104 is the prioritized candidate; the company plans to commercialize it with a hospital-based sales force if approved, and may seek partnerships for other candidates [sec_mda · as of 2026-08-13].
- The company believes existing cash will sustain operations for at least 12 months from the issuance date of its unaudited financial statements, but will require additional capital for daily needs [sec_mda · as of 2026-02-12].
What works
- The company utilizes the Section 505(b)(2) regulatory pathway, which can leverage existing safety and efficacy data of approved compounds, potentially reducing development time and cost [sec_mda · as of 2026-06-18].
- Grace Therapeutics holds worldwide commercialization rights for all pipeline candidates, providing flexibility to maximize value through direct sales or partnerships [sec_mda · as of 2026-08-13].
- The intellectual property portfolio of over 79 granted and pending patents provides a foundation for market exclusivity [sec_mda · as of 2026-06-18].
What to weigh
- The company has no approved products and does not expect to generate revenue from product sales unless and until GTx-104 obtains regulatory approval, which is subject to significant uncertainty [sec_mda · as of 2026-02-12].
- Grace Therapeutics relies on third parties for manufacturing of clinical and commercial supplies, which could delay or disrupt commercialization if those parties fail to meet quality or regulatory standards [sec_mda · as of 2026-06-18].
- The company will require additional capital to fund daily operations, and raising capital may cause dilution to existing stockholders or require relinquishing rights to technologies or drug candidates [sec_mda · as of 2025-06-23].
From the filings
Quoted directly from source documents.
The company is focused on rare and orphan diseases using novel drug delivery technologies.
“We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies.”
SEC MD&A · August 13, 2026
GTx-104 is the prioritized pipeline candidate.
“Currently, we have prioritized the development of GTx-104 over that of GTx-102 and GTx-101.”
SEC MD&A · August 13, 2026
The company believes existing cash will sustain operations for at least 12 months.
“The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of these unaudited condensed consolidated financial statements.”
SEC MD&A · February 12, 2026
The company will require additional capital and does not expect product revenue until GTx-104 approval.
“The Company will require additional capital to fund its daily operating needs. The Company does not expect to generate revenue from product sales unless and until it obtains regulatory approval for GTx-104, which is subject to significant uncertainty.”
SEC MD&A · February 12, 2026
Risks & what to watch (4)›
Key risks
- Regulatory approval uncertainty — GTx-104 may not receive regulatory approval; no revenue is expected until approval, which is highly uncertain [sec_mda · as of 2026-02-12].
- Dependence on third-party manufacturers — Reliance on third parties for manufacturing could delay or halt commercialization if they fail to meet quality or regulatory standards [sec_mda · as of 2026-06-18].
- Need for additional capital — The company requires further funding for daily operations; raising capital may cause dilution or restrict operations [sec_mda · as of 2025-06-23].
- Commercialization and partnership risks — Success of commercialization or partnerships for GTx-104, GTx-102, and GTx-101 is uncertain; partners may not devote sufficient resources [sec_mda · as of 2026-06-18].
What to watch
- Regulatory decision on GTx-104, as it is the prioritized candidate and key to potential revenue generation [sec_mda · as of 2026-08-13].
- Cash runway and any additional capital raises, given the company's need for funding beyond the next 12 months [sec_mda · as of 2026-02-12].
- Potential out-licensing or sale of GTx-102 and/or GTx-101, which could provide non-dilutive capital or strategic partnerships [sec_mda · as of 2026-08-13].
- Progress of pre-commercial planning and sales force buildout for GTx-104, if approved [sec_mda · as of 2026-02-12].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Grace Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Grace Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.0 months
D/E 0.04 · 0% dilution
Lead: BLA Filed
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$11.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 803,312 | $3.7M |
| bank of america corp /de/ | 494,723 | $2.3M |
| renaissance technologies llc | 243,910 | $1.1M |
| jane street group, llc | 167,097 | $774K |
| susquehanna international group, llp | 112,800 | $522K |
| citadel advisors llc | 98,742 | $457K |
| marshall wace, llp | 91,416 | $423K |
| connective capital management, llc | 84,549 | $391K |
| quadrature capital ltd | 66,822 | $309K |
| xtx topco ltd | 63,094 | $292K |
Showing top 10 of 32 institutional holders of Grace Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 16.7%
- Days to cover
- 1.6
- Shares short
- 2,199,232
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRCE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Grace Therapeutics, Inc.?
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, with its lead candidate GTx-104 under regulatory review.
What is Grace Therapeutics, Inc.'s lead drug candidate?
Grace Therapeutics, Inc.'s most advanced tracked candidate is gtx-104 (BLA Filed) for aneurysmal subarachnoid hemorrhage (aSAH).
Who is the CEO of Grace Therapeutics, Inc.?
Mr. Prashant Kohli is the chief executive officer of Grace Therapeutics, Inc. (GRCE).
Where is Grace Therapeutics, Inc. headquartered?
Grace Therapeutics, Inc. (GRCE) is headquartered in Princeton, NJ, United States.
What therapeutic areas does Grace Therapeutics, Inc. focus on?
Grace Therapeutics, Inc. develops therapies across Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.